CCX140 / CSL Behring, Amgen 
Welcome,         Profile    Billing    Logout  

2 Trials

   Remove FilterRemove Filter

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
CCX140 / Amgen, CSL Behring
2017-003022-32: An open, dose escalation study in patients with Primary Focal Segmental Glomerulosclerosis (FSGS - a type of glomerular disease causes scarring in the kidney) and Nephrotic Syndrom (collection of symptoms due to kidney damage)

Not yet recruiting
2
13
Europe
CCX140-B, Tablet
ChemoCentryx, Inc., ChemoCentryx, Inc.
Primary Focal Segmental Glomerulosclerosis (FSGS), A type of glomerular disease (disease damaging the glomeruli, the filtering units inside the kidney where blood is cleaned) that causes scarring (sclerosis) in kidney., Diseases [C] - Immune System Diseases [C20]
 
 
NCT03703908: A Study of CCX140-B in Subjects With Primary FSGS and Nephrotic Syndrome

Hourglass Jul 2020 - Dec 2020 : From LUMINA-2 trial for nephrotic focal segmental glomerulosclerosis
Terminated
2
5
US
CCX140-B
ChemoCentryx
Focal Segmental Glomerulosclerosis
06/20
06/20

Download Options